iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern
22.12.2021 14:18:00 EET | Business Wire | Press release
iXensor Co., Ltd. (6734.TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005223/en/
iXensor's PixoTest COVID-19 Antigen Test effectively detects Omicron and other key variants of concern (Photo: Business Wire)
iXensor, the pioneer of mobile health, declares that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies.
In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control.
Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.
Although vaccines have become widely available, Omicron has a higher chance of causing breakthrough infections and fundamentally changing the landscape of the pandemic across the globe. Rapid tests that cannot detect the Omicron variant make for a worrying prospect because false-negative results could potentially lull people into a false sense of security.
The CEO of iXensor, Dr. Carson Chen, commented "Now more than ever, Omicron-detectable frequent testing remains a critical part of COVID-19 response to keep communities open, employees and students safe, and enable people to resume traveling with less fear."
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, diabetes, diabetes and cardiovascular diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005223/en/
Contact information
Media Contact
Spokesperson: Patrick Liao
Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-928-570-208
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA25.8.2026 17:40:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The approval is supported by results from the Phase 3 HERIZON-GEA-01 trial, which were published in The New England Journal of Medicine earlier this year. GEA, which includes adenocarcinomas of the stomach, gastroesophageal junction and esophagus, remains an area of substantial unmet need in the United States, with more than 31,000 new stomach cancer cases diagnosed each year.1 Approximately 20% of patients with GEA have HER2+ disease, a subtype that has historically been difficult to treat.2,3,
Gatik Raises $200 Million; Series D Led by QIA and KDT as Demand for Driverless Commercial Freight Accelerates25.8.2026 16:00:00 EEST | Press release
Gatik, the leader in autonomous trucking, today announced $200 million in financing as demand accelerates for driverless commercial freight across Fortune 50 retail, grocery and CPG supply chains. The Series D round was led by Qatar Investment Authority (QIA) and Koch Disruptive Technologies (KDT), with participation from Millennium Management, ARK Invest, Intact Private Capital and others. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825490075/en/ Gatik Announces Series D round Gatik has built one of the most commercially advanced businesses in autonomous freight, with more than $600 million in contracted revenue, 85,000 fully driverless orders completed, and 99% on-time delivery across its operations. Its trucks move goods across high-frequency regional networks between distribution centers and stores, giving customers a reliable way to add capacity, improve service levels and keep products moving. “This round, led by
Safe Software Opens Registration for the Peak of Data and AI 2027 With More Accessible Access Packages25.8.2026 16:00:00 EEST | Press release
Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, has announced that registration is open for the Peak of Data and AI 2027, its global conference for data and AI professionals, taking place March 9 to 11, 2027 at the QEII Centre in London, UK. The news builds on Safe's announcement in March 2026 that London would host the biennial conference, which has previously been held in Vancouver, Canada, Bonn, Germany and Seattle, Washington, and draws attendees from North America, Europe, Asia-Pacific, and beyond. Alongside opening registration, Safe has introduced a revised set of access packages designed to bring a broader range of professionals to the event: Free passes for public sector and government professionals, from any country One-day passes, for attendees who are unable to join for all three days Lower pricing across every pass type, including the pre-conference training add-on All attendees will also have access to a free AI training se
SLB Selected as Strategic Reservoir Partner for the Havstjerne Carbon Storage Project25.8.2026 15:46:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been selected as strategic reservoir partner for the Havstjerne carbon storage project in the Norwegian North Sea, providing technology and engineering services for the concept and front-end engineering and design (FEED) phases. The Havstjerne project is a large-scale offshore carbon storage development in Norway intended to serve industrial emitters across Europe, operated by Harbour Energy (LSE: HBR) in consortium with Stella Maris CCS, a Yinson Production company. SLB will coordinate an integrated project scope that connects analysis of the underground storage reservoir with injection well design, subsea infrastructure and plans for monitoring stored CO2 as the Havstjerne partnership develops the project’s technical, cost and schedule basis ahead of a final investment decision. The scope includes concept and FEED studies delivered through close collaboration between SLB and its OneSubsea™ joint venture. "Carbon
Moody’s Brings Its Decision-Grade Intelligence to Gemini Enterprise for Financial Services25.8.2026 15:05:00 EEST | Press release
Moody’s Corporation (NYSE: MCO) today announced that its connected intelligence is now available in Google Cloud’s Gemini Enterprise for Financial Services through the Moody’s Credit Model Context Protocol (MCP) server. As a launch partner for Google Cloud’s Gemini Enterprise for Financial Services, Moody’s gives financial professionals working in the platform direct access to credit ratings and research from Moody’s Ratings, along with Moody’s curated intelligence on companies, entities, and risk. “Delivering decision-grade intelligence wherever financial professionals work is how we help our customers stay ahead as agentic AI reshapes financial workflows,” said Ana Meauta, Managing Director, Channel Sales Partnerships at Moody’s. “With Gemini Enterprise for Financial Services, our customers can access Moody’s connected intelligence directly, bringing contextualized, decision-grade data to the point of decision.” Gemini Enterprise for Financial Services is Google Cloud’s industry-spec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom